Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Dalteparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms Caravaggio
- 13 Nov 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 13 Nov 2019 Status has been changed to active, no longer recruiting.
- 11 Sep 2018 New trial record